Key result
LDL receptor-targeted therapies lower cardiovascular mortality and drive novel treatments for dyslipidemias.
Answers are grounded in this paper and cite their sources.
Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for cardiovascular disease (CVD), and reduction of elevated LDL-C reduces mortality in patients at risk. This benefit has evolved from the use of statins and knowledge of the LDL receptor (LDLR). The most potent drugs used for dyslipidemias act by mechanisms that involve this receptor. Advances in molecular genetics and understanding of the regulation of this receptor have revealed several pharmacological targets that are being explored to develop more targeted therapies for dyslipidemias.
No takes yet. Share an insight, caveat, or question.
John Vincent (2014) conducted a review in Elevated low-density lipoprotein cholesterol (LDL-C) / Dyslipidemia. LDL receptor (LDLR) targeted therapies was evaluated. Therapies targeting the LDL receptor, such as statins, are central to reducing mortality in cardiovascular disease and guide the development of new targeted pharmacological treatments for dyslipidemias.
Synapse has enriched 10 related papers. Consider them for comparative context: